3.05
-0.19 (-5.86%)
3.12
+0.07 (+2.3%)
We assign a fundamental rating of 2 out of 10 to OBLN. OBLN was compared to 185 industry peers in the Health Care Equipment & Supplies industry. OBLN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OBLN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
OBLN had negative earnings in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.81% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -1387.25% | ||
| PM (TTM) | -1391.09% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OBLN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
OBLN has an Altman-Z score of -14.40. This is a bad value and indicates that OBLN is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for OBLN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.4 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 1.86 indicates that OBLN should not have too much problems paying its short term obligations.
OBLN has a Quick Ratio of 1.86. This is a normal value and indicates that OBLN is financially healthy and should not expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.86 | ||
| Quick Ratio | 1.86 |
3. Growth
3.1 Past
OBLN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.15%, which is quite impressive.
Looking at the last year, OBLN shows a very negative growth in Revenue. The Revenue has decreased by -64.65% in the last year.
Measured over the past years, OBLN shows a very negative growth in Revenue. The Revenue has been decreasing by -17.03% on average per year.
EPS 1Y (TTM)76.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.43%
Revenue 1Y (TTM)-64.65%
Revenue growth 3Y-45.69%
Revenue growth 5Y-17.03%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, OBLN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.38% on average per year.
Based on estimates for the next years, OBLN will show a very strong growth in Revenue. The Revenue will grow by 369.34% on average per year.
EPS Next Y43.12%
EPS Next 2Y29.83%
EPS Next 3Y22.16%
EPS Next 5Y17.38%
Revenue Next Year953.33%
Revenue Next 2Y274.17%
Revenue Next 3Y334.11%
Revenue Next 5Y369.34%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
OBLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OBLN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -2.11 |
4.3 Compensation for Growth
A more expensive valuation may be justified as OBLN's earnings are expected to grow with 22.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.83%
EPS Next 3Y22.16%
5. Dividend
5.1 Amount
OBLN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.05
-0.19 (-5.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners45.04%
Ins Owner Change0%
Market Cap30.57M
Revenue(TTM)808.00K
Net Income(TTM)-11.24M
Analysts0
Price Target18.82 (517.05%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 37.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.03 | ||
| P/tB | N/A | ||
| EV/EBITDA | -2.11 |
EPS(TTM)-3.17
EYN/A
EPS(NY)-1.5
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.08
BVpS1.01
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.81% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -1387.25% | ||
| PM (TTM) | -1391.09% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.86 | ||
| Quick Ratio | 1.86 | ||
| Altman-Z | -14.4 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.43%
EPS Next Y43.12%
EPS Next 2Y29.83%
EPS Next 3Y22.16%
EPS Next 5Y17.38%
Revenue 1Y (TTM)-64.65%
Revenue growth 3Y-45.69%
Revenue growth 5Y-17.03%
Sales Q2Q%-100%
Revenue Next Year953.33%
Revenue Next 2Y274.17%
Revenue Next 3Y334.11%
Revenue Next 5Y369.34%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
Obalon Therapeutics Inc / OBLN FAQ
What is the fundamental rating for OBLN stock?
ChartMill assigns a fundamental rating of 2 / 10 to OBLN.
What is the valuation status for OBLN stock?
ChartMill assigns a valuation rating of 2 / 10 to Obalon Therapeutics Inc (OBLN). This can be considered as Overvalued.
Can you provide the profitability details for Obalon Therapeutics Inc?
Obalon Therapeutics Inc (OBLN) has a profitability rating of 1 / 10.
What is the financial health of Obalon Therapeutics Inc (OBLN) stock?
The financial health rating of Obalon Therapeutics Inc (OBLN) is 2 / 10.
How sustainable is the dividend of Obalon Therapeutics Inc (OBLN) stock?
The dividend rating of Obalon Therapeutics Inc (OBLN) is 0 / 10 and the dividend payout ratio is 0%.